tetano
Editor, Senior Moderator
Antivir Ther. 2012 Oct 30. doi: 10.3851/IMP2442. [Epub ahead of print]
A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults.
Ison MG, Hui DS, Clezy K, O'Neil BJ, Flynt A, Collis PJ, Simon TJ, Alexander WJ.
Source
Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. mgison@northwestern.edu.
Abstract
BACKGROUND:
Seasonal interpandemic influenza causes over 200,000 annual hospitalizations in the United States. Optimal antiviral treatment in hospitalized patients is not established.
METHODS:
During three interpandemic influenza seasons, 137 patients hospitalized with suspected acute influenza were randomized to 5-day treatment with intravenous peramivir 400 mg or 200 mg once daily or oral oseltamivir 75 mg twice daily. Time to clinical stability and quantitative changes in viral titers from nasopharyngeal specimens were primary and key secondary endpoints.
RESULTS:
Infection was confirmed in 122 patients with influenza A (H1N1), influenza A (H3N2), or influenza B. Median times (95% CI) to clinical stability were: 37.0 hours (22.0, 48.7) peramivir 400 mg; 23.7 hours (16.0, 38.9) peramivir 200 mg; and 28.1 hours (22.0, 37.0) oseltamivir (p=0.306). Patients (n=97) who were clinically unstable at enrollment had median times to clinical stability (95% CI) of: 24.3 hours (21.2, 47.5) peramivir 400 mg; 31.0 hours (17.2, 47.7) peramivir 200 mg; and 35.5 hours (23.3, 37.9) oseltamivir (p=0.541). Titers of influenza A viruses in nasopharyngeal specimens decreased similarly across treatments but more rapid decreases in titers of influenza B occurred with peramivir treatment. There were no deaths among patients with confirmed influenza and the incidence of adverse events was low and generally similar among treatment groups.
CONCLUSIONS:
Treatment of acute seasonal influenza in hospitalized adults with either peramivir or oseltamivir resulted in generally similar clinical outcomes. Treatment with peramivir was generally safe and well tolerated and could be of benefit in this population.
PMID:
23111657
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23111657
A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults.
Ison MG, Hui DS, Clezy K, O'Neil BJ, Flynt A, Collis PJ, Simon TJ, Alexander WJ.
Source
Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. mgison@northwestern.edu.
Abstract
BACKGROUND:
Seasonal interpandemic influenza causes over 200,000 annual hospitalizations in the United States. Optimal antiviral treatment in hospitalized patients is not established.
METHODS:
During three interpandemic influenza seasons, 137 patients hospitalized with suspected acute influenza were randomized to 5-day treatment with intravenous peramivir 400 mg or 200 mg once daily or oral oseltamivir 75 mg twice daily. Time to clinical stability and quantitative changes in viral titers from nasopharyngeal specimens were primary and key secondary endpoints.
RESULTS:
Infection was confirmed in 122 patients with influenza A (H1N1), influenza A (H3N2), or influenza B. Median times (95% CI) to clinical stability were: 37.0 hours (22.0, 48.7) peramivir 400 mg; 23.7 hours (16.0, 38.9) peramivir 200 mg; and 28.1 hours (22.0, 37.0) oseltamivir (p=0.306). Patients (n=97) who were clinically unstable at enrollment had median times to clinical stability (95% CI) of: 24.3 hours (21.2, 47.5) peramivir 400 mg; 31.0 hours (17.2, 47.7) peramivir 200 mg; and 35.5 hours (23.3, 37.9) oseltamivir (p=0.541). Titers of influenza A viruses in nasopharyngeal specimens decreased similarly across treatments but more rapid decreases in titers of influenza B occurred with peramivir treatment. There were no deaths among patients with confirmed influenza and the incidence of adverse events was low and generally similar among treatment groups.
CONCLUSIONS:
Treatment of acute seasonal influenza in hospitalized adults with either peramivir or oseltamivir resulted in generally similar clinical outcomes. Treatment with peramivir was generally safe and well tolerated and could be of benefit in this population.
PMID:
23111657
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23111657